Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS phase 3 ravulizumab study in CKD patients undergoing cardiac surgery with cardiopulmonary bypass
NL-OMON59539Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ravulizumab in acute kidney failure (AKF) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: MAKE90. Started May 2024; status: completed.
02
Drugs
ravulizumab
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON59539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59539.